No Correlation Between Estrogen Metabolites, Colorectal Cancer Risk
the Cancer Therapy Advisor take:
Estrogen metabolites (EM), including estrone and estradiol, have no relationship to colorectal cancer (CRC) in postmenopausal women, according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in the study included 15,595 women between 55 to 80 years who donated blood between 1992 and 1993 for cancer through December 2004. A panel of 15 EM (eg, estrone and estradiol) was measured from 187 cases of CRC.
Results showed no significant associations between estrone (HRQ4 v Q1 = 1.15; 95% CI: 0.69, 1.93; Ptrend =0.54), estradiol (HRQ4 v Q1= 0.98; 95% CI: 0.58, 1.64; Ptrend >0.99) or total EM (the sum of all EM; HRQ4 v Q1=1.35; 95% CI: 0.81, 2.24; Ptrend=0.33) and CRC risk.
Specifically, the metabolites with a 2-, 4-, or 16-pathway had no related risk. However, a borderline trend was observed with high levels of 17-epiestriol.
The study suggests that future research focus on understanding how exogenous estrogen may be associated with prevention of CRC.
Estrogen metabolites, including estrone and estradiol, have no relationship to colorectal cancer in postmenopausal women.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol